Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4+ T Cells of Patients with Relapsing-Remitting Multiple Sclerosis
Figure 4
TGFBR2 and miR-106b expression analysis. (a) Transcriptional expression of TGFBR2 was analyzed with real-time RT-PCR in freshly isolated CD4+ T cells from HVs transiently transfected by electroporation (EP) with 1 μM of miR-17 synthetic inhibitor (ImiR-17) or vehicle control (mock) () (bars represent mean with SEM) and (b) in CD4+ T cells from HVs and untreated and natalizumab treated patients (). (c) Analysis of transcriptional expression of miR-106b in CD4+ T cells from HVs and untreated and natalizumab treated patients (). Bars represent median with interquartile range. Relative expression levels are depicted. One-way ANOVA with Tukey’s multiple comparison test was applied.,;; n.s.: not significant.